X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
alectinib (350) 350
crizotinib (248) 248
oncology (205) 205
index medicus (203) 203
humans (140) 140
chemotherapy (138) 138
ceritinib (130) 130
anaplastic lymphoma kinase (123) 123
open-label (116) 116
lung cancer (109) 109
lung neoplasms - drug therapy (99) 99
alk (94) 94
carcinoma, non-small-cell lung - drug therapy (89) 89
lymphomas (84) 84
lung cancer, non-small cell (83) 83
non-small cell lung cancer (77) 77
mutation (75) 75
cell lung-cancer (70) 70
resistance (70) 70
nsclc (66) 66
protein kinase inhibitors - therapeutic use (65) 65
female (61) 61
male (61) 61
lung neoplasms - genetics (57) 57
pharmacology & pharmacy (57) 57
brain metastases (55) 55
respiratory system (55) 55
receptor protein-tyrosine kinases - genetics (53) 53
kinases (52) 52
carcinoma, non-small-cell lung - genetics (51) 51
middle aged (51) 51
acquired-resistance (49) 49
cancer (49) 49
hemic and lymphatic diseases (49) 49
safety (49) 49
receptor protein-tyrosine kinases - antagonists & inhibitors (48) 48
metastasis (46) 46
carbazoles - therapeutic use (45) 45
crizotinib resistance (45) 45
lymphoma (45) 45
piperidines - therapeutic use (45) 45
lung neoplasms - pathology (43) 43
antineoplastic agents - therapeutic use (42) 42
carcinoma, non-small-cell lung - pathology (42) 42
patients (40) 40
protein kinase inhibitors - pharmacology (40) 40
adult (39) 39
antitumor-activity (39) 39
protein-tyrosine kinase (39) 39
brigatinib (38) 38
adenocarcinoma (37) 37
cancer therapies (36) 36
non-small cell lung carcinoma (36) 36
single-arm (33) 33
non-small-cell lung cancer (32) 32
aged (30) 30
animals (30) 30
inhibitor alectinib (30) 30
metastases (30) 30
care and treatment (29) 29
drug therapy (29) 29
mutations (29) 29
neoplasms. tumors. oncology. including cancer and carcinogens (29) 29
tumors (29) 29
tyrosine (29) 29
eml4-alk fusion gene (28) 28
inhibitor (28) 28
ch5424802 (27) 27
eml4-alk (27) 27
hematology, oncology and palliative medicine (27) 27
alk inhibitors (26) 26
case report (26) 26
drug resistance, neoplasm (26) 26
pyrazoles - therapeutic use (26) 26
pyridines - therapeutic use (26) 26
gene (25) 25
gene rearrangement (25) 25
inhibitors (25) 25
antineoplastic agents - pharmacology (24) 24
carbazoles - pharmacology (24) 24
lorlatinib (24) 24
treatment outcome (24) 24
analysis (23) 23
development and progression (23) 23
disease (23) 23
piperidines - pharmacology (23) 23
genetic aspects (22) 22
identification (21) 21
pulmonary/respiratory (21) 21
receptor protein-tyrosine kinases - metabolism (21) 21
research (21) 21
alk inhibitor (20) 20
review (20) 20
therapy (20) 20
carbazoles - administration & dosage (19) 19
lung neoplasms - enzymology (19) 19
medicine & public health (19) 19
egfr (18) 18
piperidines - administration & dosage (18) 18
pyrazoles - pharmacology (18) 18
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NATURE REVIEWS CLINICAL ONCOLOGY, ISSN 1759-4774, 02/2018, Volume 15, Issue 2, pp. 71 - 72
In 2017, major advances in the treatment of non-small-cell lung cancer (NSCLC) continued to emanate from the fields of molecularly targeted therapy and... 
ONCOLOGY | CRIZOTINIB | ALECTINIB
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2018, Volume 36, Issue 22, pp. 2251 - 2258
Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK)... 
TRIALS | ONCOLOGY | CERITINIB | ADENOCARCINOMA | ALECTINIB | INHIBITORS | PHASE-3 | RETROSPECTIVE ANALYSIS
Journal Article
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, ISSN 1556-0864, 10/2018, Volume 13, Issue 10, pp. 1530 - 1538
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 05/2018, Volume 16, Issue 5S, pp. 601 - 604
Molecular testing is recommended for initial diagnosis in patients with non-small cell lung cancer (NSCLC), according to the updated NCCN Guidelines, because... 
ONCOLOGY | CRIZOTINIB | ALECTINIB
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2018, Volume 29, Issue 6, pp. 1409 - 1416
Abstract Background This is the first trial to directly compare efficacy and safety of alectinib versus standard chemotherapy in advanced/metastatic anaplastic... 
ALK | SURVIVAL | TRIAL | crizotinib | NSCLC | ONCOLOGY | BRAIN METASTASES | OPEN-LABEL | chemotherapy | PROGRESSION | alectinib | Editor's Choice | Original
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2018, Volume 29, Issue 11, pp. 2214 - 2222
Abstract Background The phase III ALEX study in patients with treatment-naive advanced anaplastic lymphoma kinase mutation-positive (ALK+) non-small-cell lung... 
ALK-positive | Alectinib | CNS | NSCLC | ONCOLOGY | BRAIN METASTASES | OPEN-LABEL | CHEMOTHERAPY | alectinib | Original articles
Journal Article
Lung Cancer, ISSN 0169-5002, 01/2020, Volume 139, pp. 22 - 27
A pooled analysis of two open-label phase II studies of alectinib (NP28673 [NCT01801111] and NP28761 [NCT01871805]) demonstrated clinical activity in patients... 
ALK | Alectinib | Safety | NSCLC | Pooled analysis | Overall survival
Journal Article
Lung Cancer, ISSN 0169-5002, 01/2020, Volume 139, pp. 9 - 12
to report outcomes of four cases of chemo-refractory -rearranged non-small cell lung carcinomas (NSCLCs) treated with alectinib in a single center. we... 
Adenocarcinoma | Targeted-therapy | Alectinib | Lung cancer | RET-rearranged
Journal Article
Lung Cancer, ISSN 0169-5002, 12/2019, Volume 138, pp. 79 - 87
Alectinib demonstrated superior efficacy and a safety profile that compared favorably with crizotinib in treatment-naïve + non-small-cell lung cancer (NSCLC)... 
Crizotinib | ALK-positive | Alectinib | Patient-reported outcomes | NSCLC
Journal Article
CANCER SCIENCE, ISSN 1347-9032, 11/2016, Volume 107, Issue 11, pp. 1642 - 1646
We report pharmacokinetics, efficacy and safety data for a new 150-mg alectinib capsule in ALK+ non-small-cell lung cancer in a multicenter, open-label... 
NSCLC | INHIBITOR ALECTINIB | anaplastic lymphoma kinase | KINASE | OPEN-LABEL | AF-001JP | PHASE I/II | Japanese | EML4-ALK | Alectinib | ONCOLOGY | RESISTANCE | LYMPHOMA | bioequivalence | PROGRESSION | non-small-cell lung cancer
Journal Article
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, ISSN 0732-183X, 06/2019, Volume 37, Issue 16, pp. 1370 - 1379
PURPOSE Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical... 
ONCOLOGY | CERITINIB | ALECTINIB | CRIZOTINIB | OPEN-LABEL | INHIBITOR | ROS1 | PF-06463922
Journal Article
Journal Article
EBioMedicine, ISSN 2352-3964, 03/2019, Volume 41, pp. 9 - 10
Journal Article
Cancer Discovery, ISSN 2159-8274, 10/2016, Volume 6, Issue 10, pp. 1118 - 1133
Journal Article
Internal Medicine, ISSN 0918-2918, 2019
We herein report a 37-year-old woman with lung adenocarcinoma with brain metastases and an asymptomatic ovarian tumor. Immunohistochemistry and a fluorescent... 
Alectinib | ALK-rearranged lung adenocarcinoma | metastatic ovarian tumor
Journal Article
CANCER DISCOVERY, ISSN 2159-8274, 10/2018, Volume 8, Issue 10, pp. 1227 - 1236
The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA-C can result in significant clinical benefit in patients with diverse... 
CELL LUNG-CANCER | ALK | KINASE INHIBITION | ENTRECTINIB | SOLID TUMORS | ONCOLOGY | OVERCOMES CRIZOTINIB RESISTANCE | ALECTINIB | ACQUIRED-RESISTANCE | TRK | ROS1
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.